Revvity (RVTY) Wells Fargo 21st Annual Healthcare Conference summary

Acquisition and portfolio strategy

• Announced acquisition of Human Cell Design to strengthen the reagents business, enhancing capabilities from preclinical to clinical stages.

• Acquisition aligns with a strategy to build a comprehensive platform and reagents portfolio, supporting a 'razor blade' model for recurring revenue.

Financial and operational performance

• Second quarter results were in line with expectations, with diagnostics outperforming and life sciences showing modest growth.

• Pharma biotech segment is recovering, driven by reduced uncertainty and renewed investment, with momentum expected to continue.

• Margin guidance was raised twice this year, reflecting strong execution and cost initiatives, with further improvement expected into 4Q and beyond.

Market trends and customer dynamics

• Pharma biotech investment is normalizing, aided by stabilization in the macro environment and increased focus on innovation due to patent cliffs.

• AI is driving incremental investment in drug discovery, not cannibalizing traditional tool spending, and is accelerating demand for high-content screening.

• Academic and government markets remain stable but not fully normalized, with Europe more stable than the U.S.